Pulmonary Development and Disease Pathogenesis Training Program

肺部发育与疾病发病机制培训项目

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT Our Pulmonary Development and Disease Pathogenesis Training Program aims to provide advanced research training by supporting stipends for three pre-doctoral and for five post-doctoral candidates within the University of Cincinnati College of Medicine (UCCOM) and Cincinnati Children’s Hospital Medical Center (CCHMC) graduate and post-graduate training programs. The training environment draws upon established, integrated, innovative graduate and postgraduate programs focused to molecular, developmental, and cell biology and outstanding clinical, translational programs focused to pediatric and adult pulmonary diseases and radiological imaging research. The T32 program benefits from strong NHLBI-supported research programs and brings together more than 36 distinguished, NIH-funded investigators experienced in modern molecular and cell biology, physiology and imaging strategies to study lung development and diseases. Program faculty have shared research interests and active collaborations in basic and translational research. Major research themes include pathogenesis of pulmonary disorders and will also focus to the pulmonary vasculature. Gene expression among cells, function, and regulation during organ development, injury, and repair are areas of interest. Likewise, development of biomarkers, imaging, and therapeutics for lung and pulmonary vascular diseases are areas of excellence. Promising trainees engaged in pre- or post-doctoral training programs are identified and selected on a competitive basis. PhD and MD/PhD predoctoral trainees obtain their PhD degrees in Graduate Programs in Developmental Biology, Immunobiology, Biomedical Informatics, Pathobiology and Molecular Medicine or Molecular Genetics (Biochemistry-Microbiology) at the University of Cincinnati College of Medicine. Post- doctoral trainees may have an MD or PhD degree, or both, and are recruited to our T32 Mentor laboratories. Special attention is given to recruitment of minority individuals and physician scientist candidates seeking their PhD/MD degree. Research training includes mentoring in career development, training in the responsible conduct of research, reproducibility and scientific rigor, ethics in research, research presentation skills and various seminars and courses within the graduate and divisional programs in which the trainees and their training faculty participate. Trainees attend regular research meetings and pertinent seminar series. Program Administration includes the contact Co-PI and three Co-Principal Investigators, who form the Executive Committee, and both External and Internal Advisory Committees. The progress of each trainee, quality of mentors, and overall effectiveness of the program is critically reviewed annually. Trainees will meet with their Mentor regularly, the T32 Program Director and Co-Directors quarterly, and their Mentoring Committee at least biannually. This T32 renewal application (Years 25-30) will permit us to continue a program with outstanding productivity in preparing new investigators to enhance research training and competence in critical aspects of pulmonary and cardiovascular development and disease pathogenesis.
项目概要/摘要 我们的肺部发育和疾病发病机制培训计划旨在提供先进的研究 培训,为三名博士前候选人和五名博士后候选人提供津贴 辛辛那提大学医学院 (UCCOM) 和辛辛那提儿童医院医疗中心 (CCHMC) 研究生和研究生培训计划借鉴了既定的、 专注于分子、发育和细胞的综合、创新研究生和研究生课程 生物学和杰出的临床转化项目,重点关注儿科和成人肺部疾病和 T32 计划受益于 NHLBI 支持的强大研究计划和 汇集了超过 36 名由 NIH 资助、在现代分子和细胞领域经验丰富的杰出研究人员 项目教师拥有研究肺部发育和疾病的生物学、生理学和成像策略。 在基础和转化研究方面有共同的研究兴趣和积极的合作。 包括肺部疾病的发病机制,还将重点关注肺血管系统的基因表达。 同样,细胞、器官发育、损伤和修复过程中的功能和调节也是人们感兴趣的领域。 肺和肺血管疾病的生物标志物、成像和治疗方法的开发是以下领域 从事博士前或博士后培训计划的有前途的学员被确定和选择。 博士和博士/博士前培训生在研究生课程中获得博士学位。 发育生物学、免疫生物学、生物医学信息学、病理生物学和分子医学或 辛辛那提大学医学院分子遗传学(生物化学-微生物学)。 博士生可能拥有医学博士或博士学位,或两者兼而有之,并被招募到我们的 T32 导师实验室。 特别关注招募少数族裔个人和寻求其发展机会的医师科学家候选人 博士/医学博士学位研究培训包括职业发展指导、负责人培训。 研究的进行、可重复性和科学严谨性、研究道德、研究演示技巧和 研究生和部门课程内的各种研讨会和课程,其中学员及其培训 教员参加定期的研究会议和相关的研讨会计划。 管理部门包括联系人联合首席研究员和三名联合首席研究员,他们组成了执行官 委员会以及外部和内部咨询委员会 每个学员的进步、质量。 导师,并且该计划的整体有效性将受到严格审查。 定期担任导师,每季度担任 T32 项目总监和联合总监,以及至少他们的导师委员会 每半年一次的 T32 续签申请(25-30 年级)将使我们能够继续开展未完成的计划。 培养新研究者的生产力,以加强关键方面的研究培训和能力 肺和心血管的发育和疾病发病机制。

项目成果

期刊论文数量(76)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Undeniable Evidence That the Adult Mammalian Heart Lacks an Endogenous Regenerative Stem Cell.
  • DOI:
    10.1161/circulationaha.118.035186
  • 发表时间:
    2018-08-21
  • 期刊:
  • 影响因子:
    37.8
  • 作者:
    Maliken BD;Molkentin JD
  • 通讯作者:
    Molkentin JD
Modeling pulmonary alveolar microlithiasis by epithelial deletion of the Npt2b sodium phosphate cotransporter reveals putative biomarkers and strategies for treatment.
  • DOI:
    10.1126/scitranslmed.aac8577
  • 发表时间:
    2015-11-11
  • 期刊:
  • 影响因子:
    17.1
  • 作者:
    Saito A;Nikolaidis NM;Amlal H;Uehara Y;Gardner JC;LaSance K;Pitstick LB;Bridges JP;Wikenheiser-Brokamp KA;McGraw DW;Woods JC;Sabbagh Y;Schiavi SC;Altinişik G;Jakopović M;Inoue Y;McCormack FX
  • 通讯作者:
    McCormack FX
Thermal injury of the skin induces G-CSF-dependent attenuation of EPO-mediated STAT signaling and erythroid differentiation arrest in mice.
皮肤热损伤可诱导 G-CSF 依赖性 EPO 介导的 STAT 信号减弱,并导致小鼠红细胞分化停滞。
  • DOI:
    10.1016/j.exphem.2017.08.005
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    2.6
  • 作者:
    Noel,JohnG;Ramser,BenjaminJ;Cancelas,JoseA;McCormack,FrancisX;Gardner,JasonC
  • 通讯作者:
    Gardner,JasonC
Bronchopulmonary dysplasia from chest radiographs to magnetic resonance imaging and computed tomography: adding value.
  • DOI:
    10.1007/s00247-021-05250-1
  • 发表时间:
    2022-04
  • 期刊:
  • 影响因子:
    2.3
  • 作者:
    Higano NS;Bates AJ;Gunatilaka CC;Hysinger EB;Critser PJ;Hirsch R;Woods JC;Fleck RJ
  • 通讯作者:
    Fleck RJ
The effect of airway motion and breathing phase during imaging on CFD simulations of respiratory airflow.
  • DOI:
    10.1016/j.compbiomed.2020.104099
  • 发表时间:
    2020-12
  • 期刊:
  • 影响因子:
    7.7
  • 作者:
    Gunatilaka CC;Schuh A;Higano NS;Woods JC;Bates AJ
  • 通讯作者:
    Bates AJ
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Francis Xavier McCormack其他文献

Francis Xavier McCormack的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Francis Xavier McCormack', 18)}}的其他基金

Novel Mechanisms of Pulmonary Fibrosis
肺纤维化的新机制
  • 批准号:
    10660225
  • 财政年份:
    2023
  • 资助金额:
    $ 37.94万
  • 项目类别:
Role of Pulmonary Osteoclast-Like Cells in Lung Injury
肺破骨细胞样细胞在肺损伤中的作用
  • 批准号:
    10395922
  • 财政年份:
    2021
  • 资助金额:
    $ 37.94万
  • 项目类别:
Role of Pulmonary Osteoclast-Like Cells in Lung Injury
肺破骨细胞样细胞在肺损伤中的作用
  • 批准号:
    10115416
  • 财政年份:
    2021
  • 资助金额:
    $ 37.94万
  • 项目类别:
Role of Pulmonary Osteoclast-Like Cells in Lung Injury
肺破骨细胞样细胞在肺损伤中的作用
  • 批准号:
    10620655
  • 财政年份:
    2021
  • 资助金额:
    $ 37.94万
  • 项目类别:
Pulmonary Epithelial Dynamics and Innate Host Defense
肺上皮动力学和先天宿主防御
  • 批准号:
    10063952
  • 财政年份:
    2017
  • 资助金额:
    $ 37.94万
  • 项目类别:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验(MILED)-CCC
  • 批准号:
    10219338
  • 财政年份:
    2016
  • 资助金额:
    $ 37.94万
  • 项目类别:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验(MILED)-CCC
  • 批准号:
    9742512
  • 财政年份:
    2016
  • 资助金额:
    $ 37.94万
  • 项目类别:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验(MILED)-CCC
  • 批准号:
    9355218
  • 财政年份:
    2016
  • 资助金额:
    $ 37.94万
  • 项目类别:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验(MILED)-CCC
  • 批准号:
    9520409
  • 财政年份:
    2016
  • 资助金额:
    $ 37.94万
  • 项目类别:
Pathogenesis-Driven Therapeutic Development for Pulmonary Alveolar Microlithiasis
肺泡微石症的发病机制驱动的治疗开发
  • 批准号:
    9247827
  • 财政年份:
    2015
  • 资助金额:
    $ 37.94万
  • 项目类别:

相似国自然基金

GADD45α去甲基化调节泛素羧基末端水解酶L1(UCHL1)促进肺血管重构与肺血管疾病发生发展机制研究
  • 批准号:
    82370060
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
大气颗粒污染物的长期暴露对慢性阻塞性肺疾病病情发展的影响
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    57 万元
  • 项目类别:
    面上项目
不同发展速度肺脾虚损慢性阻塞性肺疾病患者血液差异蛋白筛选及相关因子验证研究
  • 批准号:
    81660740
  • 批准年份:
    2016
  • 资助金额:
    38.0 万元
  • 项目类别:
    地区科学基金项目
β2-微球蛋白诱导肺上皮细胞衰老参与慢性阻塞性肺疾病的发生发展
  • 批准号:
    81670032
  • 批准年份:
    2016
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
线粒体DNA突变在慢性阻塞性肺疾病发生发展中的作用及机制研究
  • 批准号:
    81170044
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

An Integrated Model of Contextual Safety, Social Safety, and Social Vigilance as Psychosocial Contributors to Cardiovascular Disease
情境安全、社会安全和社会警惕作为心血管疾病社会心理因素的综合模型
  • 批准号:
    10749134
  • 财政年份:
    2024
  • 资助金额:
    $ 37.94万
  • 项目类别:
Developmental mechanisms specifying vagal innervation of organ targets
指定器官目标迷走神经支配的发育机制
  • 批准号:
    10752553
  • 财政年份:
    2024
  • 资助金额:
    $ 37.94万
  • 项目类别:
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 37.94万
  • 项目类别:
Gain-of-function toxicity in alpha-1 antitrypsin deficient type 2 alveolar epithelial cells
α-1 抗胰蛋白酶缺陷型 2 型肺泡上皮细胞的功能获得毒性
  • 批准号:
    10751760
  • 财政年份:
    2024
  • 资助金额:
    $ 37.94万
  • 项目类别:
Regulation of prostate organogenesis by tissue-resident macrophages
组织驻留巨噬细胞对前列腺器官发生的调节
  • 批准号:
    10555589
  • 财政年份:
    2023
  • 资助金额:
    $ 37.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了